SynthesisClinical endocrinology2021
Long-term efficacy and safety of gonadotropin-releasing hormone analog treatment in children with idiopathic central precocious puberty: A systematic review and meta-analysis.
Synthesis in Clinical endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 5 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Metabolic changes in children with idiopathic central precocious puberty after gonadotrophin-releasing hormone agonist therapy: a meta-analysis.Frontiers in pediatrics · 2025Pooled it
- Use of gonadotropin-releasing hormone agonists in transgender and gender diverse youth: a systematic review.Frontiers in endocrinology · 2025Pooled it
- The Effect of GnRHa Treatment on Body Mass Index in Central Precocious Puberty: A Systematic Review and Meta-Analysis.Hormone research in paediatrics · 2024Pooled it
- Effect of gonadotropin-releasing hormone analogue treatment in improving final adult height of children with central precocious puberty or early and fast puberty: a Meta analysis.Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2021Pooled it
- Long-term efficacy and safety of gonadotropin-releasing hormone analog treatment in children with idiopathic central precocious puberty: A systematic review and meta-analysis.Clinical endocrinology · 2021Pooled it
- Development and validation of diagnostic prediction models for central precocious puberty in girls based on machine learning: a multicenter retrospective study.Frontiers in endocrinology · 2026Article
- Does gonadotropin-releasing hormone analogue treatment alter body mass index in boys with central precocious puberty?European journal of pediatrics · 2025Article
- Polycystic ovary syndrome and idiopathic central precocious puberty: two sides of the same coin?Endocrine · 2025Review
- Treatment of overweight and obese girls experiencing central precocious puberty: a comparison of the effectiveness of leuprolide acetate and triptorelin pamoate.Annals of pediatric endocrinology & metabolism · 2025Article
- Long-Term Efficacy and Safety of Leuprorelin Treatment in Children with Central Precocious Puberty: A Systematic Review and Meta-Analysis.Children (Basel, Switzerland) · 2025Review
- Efficacy of leuprolide acetate versus triptorelin pamoate administered every 3 months for treatment of central precocious puberty.Clinical and experimental pediatrics · 2025Article
- Gonadotropin-releasing hormone analogs treatment in girls with central precocious puberty and early fast puberty.Pediatric research · 2024Observational
- Effectiveness of leuprolide acetate administered monthly compared to three-monthly in the treatment of central precocious puberty: evaluation at the end of treatment.Frontiers in endocrinology · 2024Article
- Adult height in girls with idiopathic central precocious puberty treated with triptorelin.Frontiers in endocrinology · 2024Observational
- The effect of gonadoliberin analog treatment in precocious puberty on polycystic ovarian syndrome prevalence in adulthood.Frontiers in endocrinology · 2024Article
- Effects of different therapy regimens to increase final adult height in males at advanced bone age with idiopathic short stature.BMC pediatrics · 2023Article
- 2022 Clinical practice guidelines for central precocious puberty of Korean children and adolescents.Annals of pediatric endocrinology & metabolism · 2023Article
- Differential diagnosis of precocious puberty in girls during the COVID-19 pandemic: a pilot study.BMC pediatrics · 2023Article
- Development and validation of a model for predicting the adult height of girls with idiopathic central precocious puberty.European journal of pediatrics · 2023Article
- Benefits from the first year of GnRHa therapy in boys with idiopathic central precocious puberty when initiating treatment after age 9 years: findings from a real-world retrospective study.BMC endocrine disorders · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo investigate the long-term efficacy and safety of gonadotropin-releasing hormone analog (GnRHa) treatment in children with idiopathic central precocious puberty (CPP).
methodThe protocol was registered with International Prospective Register of Systematic Reviews (CRD42018102792). PubMed, EMBASE and the Cochrane Library were searched for eligible comparative and single-arm studies.
resultsWe identified a total of 98 studies that included 5475 individuals. The overall risk of bias of the eligible studies ranged from critical to moderate. The overall quality of evidence for each outcome ranged from very low to moderate. Evidence-based comparative studies showed that GnRHa treatment increase final adult height (FAH, cm; studies = 4, n = 242; mean difference [MD] = 4.83; 95% confidence interval [CI], 2.32 to 7.34; I
conclusionCompared with no treatment, evidence indicates that GnRHa treatment increase FAH and decrease BMI in girls with idiopathic CPP. GnRHa treatment did not evidently increase the risk of PCOS. However, evidence regarding other key long-term outcomes (such as infertility and malignant or metabolic diseases) was considered very weak to suggest the benefits or side effects of GnRHa treatment. Additional high-quality evidence is needed before firm conclusions can be drawn.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.